Beyond interferon: Rationale and prospects for newer treatment paradigms for chronic hepatitis C

Therapeutic Advances in Chronic Disease

Volumn 6, Issue 1, 2015, Pages 4-14

  Cortez, Karoll J ^a   Kottilil, Shyam ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Boceprevir; Hepatitis C; Pegylated interferon; Ribavirin; Simeprevir; Sofosbuvir; Sustained virologic response; Telaprevir

Indexed keywords

ABT 450; ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ASUNAPREVIR; BOCEPREVIR; DACLATASVIR; DASABUVIR; DELEOBUVIR; FALDAPREVIR; INTERFERON; LEDIPASVIR; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4A; NONSTRUCTURAL PROTEIN 5A; NONSTRUCTURAL PROTEIN 5B; OMBITASVIR; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; PROTEINASE INHIBITOR; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR;

ANTIVIRAL THERAPY; DNA POLYMORPHISM; DRUG RESPONSE; DRUG TARGETING; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIFE CYCLE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT RESPONSE;

EID: 84919629931     PISSN: 20406223     EISSN: 20406231     Source Type: Journal    
DOI: 10.1177/2040622314551934     Document Type: Review

References (49)

1. Alter M. Kruszon-Moran D. Nainan O. Mcquillan G. Gao F. Moyer L. et al. (1999) The Prevalence of Hepatitis C Virus Infection in the United States, 1988 through 1994. N Engl J Med 341: 556–562.
2. Armstrong G. Wasley A. Simard E. Mcquillan G. Kuhnert W. Alter M. (2006) The Prevalence of Hepatitis C Virus Infection in the United States, 1999 through 2002. Ann Intern Med 144: 705–714.
3. Bacon B. Gordon S. Lawitz E. Marcellin P. Vierling J. Zeuzem S. et al. (2011) Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 364: 1207–1217.
4. CDC (2012) Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945–1965. MMWR 61: 1–18.
5. Chayama K. Takahashi S. Toyota J. Karino Y. Ikeda K. Ishikawa H. et al. (2012) Dual therapy with the nonstructural protein 5a inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1B-infected null responders. Hepatology 55: 742–748.
6. Choo Q. Kuo G. Weiner A. Overby L. Bradley D. Houghton M. (1989) Isolation of a CDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244: 359–362.
7. Chung R. Andersen J. Volberding P. Robbins G. Liu T. Sherman K. et al. (2004) Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 351: 451–459.
8. Davis G. Alter M. El-Serag H. Poynard T. Jennings L. (2010) Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 138: 513–521, 521, e511–516.
9. Delwart E. Slikas E. Stramer S. Kamel H. Kessler D. Krysztof D. et al. (2012) Genetic diversity of recently acquired and prevalent HIV, hepatitis B virus, and hepatitis C virus infections in US blood donors. J Infect Dis 205: 875–885.
10. Flamm S. Lawitz E. Jacobson I. Bourliere M. Hezode C. Vierling J. et al. (2013) Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection. Clin Gastroenterol Hepatol 11: 81–U216.
11. Fried M. Buti M. Dore G. Flisiak R. Ferenci P. Jacobson I. et al. (2013) Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naive genotype 1 hepatitis C: The Randomized Pillar Study. Hepatology 58: 1918–1929.
12. Gane E. Stedman C. Hyland R. Ding X. Svarovskaia E. Symonds W. et al. (2013) Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 368: 34–44.
13. Germer J. Mandrekar J. Bendel J. Mitchell P. Yao J. (2011) Hepatitis C virus genotypes in clinical specimens tested at a national reference testing laboratory in the United States. J Clin Microbiol 49: 3040–3043.
14. Gilead-Sciences (2013) Sovaldi Full Prescribing Information, Valence Data.
15. Hayashi N. Seto C. Kato M. Komada Y. Goto S. (2014) Once-daily simeprevir (TMC435) with peginterferon / ribavirin for treatment-naive hepatitis C genotype 1-infected patients in Japan: The DRAGON Study. J Gastroenterol 49 (1): 138–147.
16. Hezode C. Forestier N. Dusheiko G. Ferenci P. Pol S. Goeser T. et al. (2009) Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 360: 1839–1850.
17. Hezode C. Ontaine H. Dorival C. Zoulim F. Larrey D. Canva V. et al. for the CUPIC Study Group. (2014) Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology. DOI: 10.1053/j.gastro.2014.03.051.
18. Jacobson I. Dore G. Foster G. Fried M. Radu M. Rafalskiy V. et al. (2013 a) Abstract 1425 simeorevir (TM435) with peginterferon / ribavirin for chronic HCV genotype-1 infection in treatment-naïve patients: results from QUEST-1, a phase III trial. J Hepatol 58(Suppl. 1): S574.
19. Jacobson I. Gordon S. Kowdley K. Yoshida E. Rodriguez-Torres M. Sulkowski M. et al. (2013 b) Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 368: 1867–1877.
20. Jacobson I. Mchutchison J. Dusheiko G. Di Bisceglie A. Reddy K. Bzowej N. et al. (2011) Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 364: 2405–2416.
21. Jannsen-Therapeutics (2013) Olysio Full Prescribing Information, Promise Data, Quest 1 Data, Quest 2 Data. http://www.olysio.com/shared/product/olysio/prescribing-information.pdf
22. Kowdley K. Lawitz E. Crespo I. Hassanein T. Davis M. Demicco M. et al. (2013) Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet 381: 2100–2107.
23. Kowdley K. Lawitz E. Poordad F. Cohen D. Nelson D. Zeuzem S. et al. (2014). Phase 2B trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med 370: 222–232.
24. Kumada H. Toyota J. Okanoue T. Chayama K. Tsubouchi H. Hayashi N. (2012) Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol 56: 78–84.
25. Kwo P. Lawitz E. Mccone J. Schiff E. Vierling J. Pound D. et al. (2010) Efficacy of boceprevir, an NS 3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 376: 705–716.
26. Lalezari J. Nelson D. Hyland R. Lin M. Rossi S. Symonds W. et al. (2013) 845 once daily sofosbuvir plus ribavirin for 12 and 24 weeks in treatment-naïve patients with HCV infection: the Quantum study. J Hepatol 58: S346.
27. Lawitz E. Lalezari J. Hassanein T. Kowdley K. Poordad F. Sheikh A. et al. (2013 a) Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis c infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis 13:401–408.
28. Lawitz E. Mangia A. Wyles D. Rodriguez-Torres M. Hassanein T. Gordon S. et al. (2013 b) Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 368: 1878–1887.
29. Lok A. Gardiner D. Lawitz E. Martorell C. Everson G. Ghalib R. et al. (2012) Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 366: 216–224.
30. Manos M. Shvachko V. Murphy R. Arduino J. Shire N. (2012) Distribution of hepatitis C virus genotypes in a diverse US integrated health care population. J Med Virol 84: 1744–1750.
31. Mchutchison J. Everson G. Gordon S. Jacobson I. Sulkowski M. Kauffman R. et al. (2009) Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 360: 1827–1838.
32. Mchutchison J. Gordon S. Schiff E. Shiffman M. Lee W. Rustgi V. et al. (1998) Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 339: 1485–1492.
33. Mchutchison J. Manns M. Muir A. Terrault N. Jacobson I. Afdhal N. et al. (2010) Telaprevir for previously treated chronic HCV infection. N Engl J Med 362: 1292–1303.
34. Mohd Hanafiah K. Groeger J. Flaxman A. Wiersma S. (2013) Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 57: 1333–1342.
35. Muir A. Bornstein J. Killenberg P. (2004) Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 350: 2265–2271.
36. Osinusi A. Meissner E. Lee Y. Bon D. Heytens L. Nelson A. et al. (2013) Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA 310: 804–811.
37. Pol S. Ghalib R. Rustgi V. Martorell C. Everson G. Tatum H. et al. (2012) Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2A trial. Lancet Infect Dis 12: 671–677.
38. Poordad F. Lawitz E. Kowdley K. Cohen D. Podsadecki T. Siggelkow S. et al. (2013) Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med 368: 45–53.
39. Poordad F. Mccone J. Jr Bacon B. Bruno S. Manns M. Sulkowski M. et al. (2011) Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 364: 1195–1206.
40. Poynard T. Marcellin P. Lee S. Niederau C. Minuk G. Ideo G. et al. (1998) Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 352: 1426–1432.
41. Renault P. Hoofnagle J.H. (1989) Side effects of alpha interferon. Semin Liver Dis 9: 273–277.
42. Rubbia-Brandt L. Quadri R. Abid K. Giostra E. Male P. Mentha G. et al. (2000) Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol 33: 106–115.
43. Salmon-Ceron D. Rosenthal E. Lewden C. Bouteloup V. May T. Burty C. et al. (2009) Emerging role of hepatocellular carcinoma among liver-related causes of deaths in HIV-infected patients: the French National Mortalite 2005 Study. J Hepatol 50: 736–745.
44. Sherman K. Flamm S. Afdhal N. Nelson D. Sulkowski M. Everson G. et al. (2011) Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 365: 1014–1024.
45. Sulkowski M. Gardiner D. Rodriguez-Torres M. Reddy K. Hassanein T. Jacobson I. et al. (2014) Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 370: 211–221.
46. Swain M. Lai M. Shiffman M. Cooksley W. Zeuzem S. Dieterich D. et al. (2010) A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology 139: 1593–1601.
47. Zator Z. Chung R. (2013) After the cure: management of HCV after achievement of SVR. Curr HIV / AIDS Rep 10: 428–435.
48. Zeuzem S. Andreone P. Pol S. Lawitz E. Diago M. Roberts S. et al. (2011) Telaprevir for retreatment of HCV infection. N Engl J Med 364: 2417–2428.
49. Zeuzem S. Soriano V. Asselah T. Bronowicki J. Lohse A. Mullhaupt B. et al. (2013) Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med 369: 630–639.